UTHealth Houston at ObesityWeek 2026

Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website

UTHealth Houston brings 12 presentations to ObesityWeek 2026 in National Harbor. Its program centers on newer obesity drugs, from amylin analogues and CagriSema doses in REDEFINE 9 to switching from injections to oral treatment. Other work uses proteomics and integrative omics to explain how semaglutide works and what drives its gastrointestinal side effects.

OrganizationObesityWeek 2026 Attendance
UTHealth Houston
Houston, TX
Universities & research institutes
UT System health sciences university in the Texas Medical Center.
Talk
Sun Nov 15
7:30am–8:30am
Weight Management Foundayo
Peer-led review of dosing, efficacy and safety for a once-daily oral obesity medicine for adults, with time for audience questions.
Talk hosted by Eli Lilly
Metabolism and integrative physiologyPopulation health and epidemiologyNutrition, diet and food
Talk
Sun Nov 15
11:45am–1:15pm
Treating Obesity First: Exploring the Role of Amylin Analogues in the Future of Obesity Care
Reviews trial data on amylin analogues, which act through a different hormone pathway than GLP-1, as single or combination obesity treatments.
Talk hosted by Zealand Pharma
with knownwell, Pennington Biomedical Research Center
Interventional and clinical studiesNutrition, diet and food
Poster
Sun Nov 15
2:30pm–3:30pm
Session
Sun Nov 15
5:00pm–6:30pm
TRIUMPH Program and SURMOUNT-ADOLESCENTS Study Oral Session
Woodrow Wilson, Ballroom Level
Interventional and Clinical Studies · Pediatrics · Chronic Disease
Talk
Sun Nov 15
5:40pm–6:00pm
Putting TRIUMPH into Practice: Potential Clinical Implications Across the Obesity Continuum
Woodrow Wilson, Ballroom Level
Interventional and Clinical Studies · Pediatrics · Chronic Disease
Talk
Sun Nov 15
6:30pm–9:00pm
Obesity in Focus: Today's Evidence. Tomorrow's Possibilities.
Speakers cover what has changed in obesity guidelines, evidence behind approved obesity drugs, and the biology of amylin and new amylin analog data.
Talk hosted by Novo Nordisk
with UT Southwestern Medical Center, University of Zurich, Washington Center for Weight Management & Research +1 more
Interventional and clinical studiesClinical obesity care and professional practiceNutrition, diet and foodObesity pharmacotherapy and drug development
Session
Mon Nov 16
1:30pm–2:30pm
Beyond the Injection: Navigating the Switch to Oral Obesity Treatment Options
Covers when and why to move patients from injected to newer oral obesity drugs, and practical steps for managing the switch.
Clinical obesity care and professional practiceObesity pharmacotherapy and drug development
Session
Tue Nov 17
10:00am–11:00am
Merging Modalities: A Unified Approach to Treating the Patient with BMI >35
Covers why many people with severe obesity miss effective treatment and how to order drugs, metabolic surgery and other options for each patient.
Woodrow Wilson, Ballroom Level
Clinical obesity care and professional practiceBariatric surgery and devicesObesity pharmacotherapy and drug development

Explore the full ObesityWeek 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in National Harbor. Leave your work email and we’ll be in touch.

Privacy

Download the full ObesityWeek 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at UTHealth Houston

Tell us what you sell and we’ll find the people at UTHealth Houston most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction